The estimated Net Worth of Phyllis Gardner is at least $502 Mille dollars as of 16 March 2018. Phyllis Gardner owns over 5,333 units of CohBar Inc stock worth over $3,583 and over the last 11 years he sold CWBR stock worth over $0. In addition, he makes $498,843 as Independent Director at CohBar Inc.
Sign up
Phyllis Gardner CWBR stock SEC Form 4 insiders trading
Phyllis has made over 2 trades of the CohBar Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 5,333 units of CWBR stock worth $13,599 on 16 March 2018.
The largest trade he's ever made was exercising 33,064 units of CohBar Inc stock on 21 August 2017 worth over $70,096. On average, Phyllis trades about 1,828 units every 10 days since 2014. As of 16 March 2018 he still owns at least 8,333 units of CohBar Inc stock.
You can see the complete history of Phyllis Gardner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Phyllis Gardner biography
Dr. Phyllis I. Gardner M.D. serves as Independent Director of the Company. Dr. Gardner joined our Board in February 2019. Dr. Gardner has over 35 years of experience in the medical industry and academia. Dr. Gardner is currently a tenured professor at the School of Medicine at Stanford University, where she has served in various positions since 1984, and is a member of the board of directors of the Harvard Medical School of Fellows and Advisory Council on Education. Dr. Gardner has served as a director of Revance Therapeutics, Inc. (NASDAQ: RVNC), a biotechnology company, since December 2008, and previously served on the board of directors of Corium International, Inc., a biopharmaceutical company formerly listed on NASDAQ, from November 2007 to November 2018. From September 2014 to September 2015, Dr. Gardner served as a director of Parnell Pharmaceuticals Holdings Ltd. (OTCMKTS: PARNF). From 1999 to 2014, Dr. Gardner served as an adjunct partner, then partner at Essex Woodlands Health Ventures, a healthcare growth equity and venture capital firm. She also served as an independent director of various biopharmaceutical companies from 1998 to 2005. From 1994 to 1998, Dr. Gardner served as strategist and then vice president of research and head of the technology institute of Alza Corporation. Dr. Gardner’s research has centered on cardiac arrhythmias, ion channel biophysiology, cell biology, cystic fibrosis pathogenesis, gene therapy and diagnosis, and her clinical work has concentrated on medicine and cardiology. Dr. Gardner received her bachelor’s degree in biology from the University of Illinois and her M.D. from Harvard Medical School. Dr. Gardner’s industry and private equity experience, together with her experience serving on other healthcare companies’ boards, make her an important contributor to our Board.
What is the salary of Phyllis Gardner?
As the Independent Director of CohBar Inc, the total compensation of Phyllis Gardner at CohBar Inc is $498,843. There are 1 executives at CohBar Inc getting paid more, with Steven Engle having the highest compensation of $2,410,850.
How old is Phyllis Gardner?
Phyllis Gardner is 69, he's been the Independent Director of CohBar Inc since 2019. There are 2 older and 11 younger executives at CohBar Inc. The oldest executive at CohBar Inc is Albion Fitzgerald, 71, who is the Independent Chairman of the Board.
What's Phyllis Gardner's mailing address?
Phyllis's mailing address filed with the SEC is 1775 WEST OAK COMMONS COURT, , MARIETTA, GA, 30062.
Insiders trading at CohBar Inc
Over the last 7 years, insiders at CohBar Inc have traded over $0 worth of CohBar Inc stock and bought 586,523 units worth $136,480 . The most active insiders traders include Misha Petkevich, Kenneth C Cundy e Jon Leland Stern. On average, CohBar Inc executives and independent directors trade stock every 22 days with the average trade being worth of $9,727. The most recent stock trade was executed by David Greenwood on 1 November 2021, trading 20,000 units of CWBR stock currently worth $8,600.
What does CohBar Inc do?
cohbar (otcqx: cwbr and tsxv: cob.u) is the leader in the research and development of mitochondria-based therapeutics (mbts), an emerging class of drugs for the treatment of diseases associated with aging. mbts originate from the discovery of a novel group of peptides within the genome of mitochondria, the powerhouses of the cell. this groundbreaking discovery was made by our founders, world leaders in the biology of aging, metabolism and mitochondrial genomics. mbts offer the potential to address a broad range of diseases such as type 2 diabetes, cancer, atherosclerosis and neurodegenerative disorders.
What does CohBar Inc's logo look like?
Complete history of Phyllis Gardner stock trades at MiMedx Inc, Revance Therapeutics Inc e CohBar Inc
CohBar Inc executives and stock owners
CohBar Inc executives and other stock owners filed with the SEC include:
-
Steven Engle,
Chief Executive Officer, Director -
Phyllis Gardner,
Independent Director -
Dr. Kenneth C. Cundy,
Chief Scientific Officer -
Jeffrey F. Biunno CPA, M.B.A., CPA, MBA,
CFO, Treasurer & Sec. -
Kenneth Cundy,
Chief Scientific Officer -
David Greenwood,
Independent Director -
Jeffrey Biunno,
Chief Financial Officer, Treasurer, Secretary -
Jon Stern,
Director -
Misha Petkevich,
Independent Director -
Albion Fitzgerald,
Independent Chairman of the Board -
Pinchas Cohen,
Independent Director -
Nir Barzilai,
Independent Director -
Jordyn Tarazi,
Director of Investor Relations -
Dr. Rohit Loomba,
Scientific Consultant -
Dr. Changhan David Lee Ph.D.,
Consultant of Mitochondrial Biology -
Dr. David Andrew Sinclair A.O., Ph.D.,
Co-Founder, Advisor & Consultant -
Dr. Joseph J. Sarret,
CEO & Director -
Simon Allen,
Chief Executive Officer -
Marc E. Goldberg,
-
Philippe Calais,
Director -
Joseph J. Sarret,
Chief Executive Officer -
John Amatruda,
Director -
Carol Nast,
Director -
Joanne Yun,
Director -
Stephanie Tozzo,
Director